Chandrasekar P H, Sluchak J A
Department of Internal Medicine, Harper Hospital, Detroit, MI 48201.
Infection. 1991 Jan-Feb;19(1):49-53. doi: 10.1007/BF01643761.
We compared the in-vitro activity of cefoperazone-sulbactam (2:1), other beta-lactams, amino-glycosides and ciprofloxacin against cefoperazone-susceptible and -resistant nosocomial gram-negative bacilli. Resistant isolates including Pseudomonas aeruginosa were susceptible to cefoperazone-sulbactam; the susceptible isolates had modestly increased susceptibility to the combination. Sulbactam, by itself, was poorly active. Among others tested, ciprofloxacin and imipenem were the most active. No inoculum effect was seen with cefoperazone-sulbactam and this drug combination had a prolonged post-antibiotic effect. Cefoperazone-sulbactam is an attractive candidate for evaluation in the treatment of nosocomial infections due to aerobic gram-negative bacilli.
我们比较了头孢哌酮-舒巴坦(2:1)、其他β-内酰胺类药物、氨基糖苷类药物和环丙沙星对头孢哌酮敏感及耐药的医院内革兰氏阴性杆菌的体外活性。包括铜绿假单胞菌在内的耐药菌株对头孢哌酮-舒巴坦敏感;敏感菌株对该联合用药的敏感性略有增加。舒巴坦单独使用时活性较差。在其他测试药物中,环丙沙星和亚胺培南活性最强。头孢哌酮-舒巴坦未观察到接种物效应,且该药物组合具有较长的抗生素后效应。头孢哌酮-舒巴坦是用于评估治疗需氧革兰氏阴性杆菌引起的医院感染的有吸引力的候选药物。